Table 3: Univariate and multivariate analysis of the factors associated with SVR to peginterferon alfa-2b and ribavirin therapy.

Univariate analysisMultivariate analysis
RR (95% CI) RR (95% CI)

Age 57 years0.6461.24 (0.50–3.09)
SexFemale0.6340.80 (0.33–1.97)
BMI 23 kg/m20.2211.86 (0.69–5.02)
Underlying liver disease
CH0.8721.15 (0.21–6.32)
WBC 5100 / L0.8270.75 (0.37–2.22)
Hb 14.0 g/dL0.3170.62 (0.25–1.58)
Plt 20 × 104/ L0.1122.10 (0.84–5.24)
AST 40 IU/L0.4291.44 (0.58–3.55)
ALT 52 IU/L0.6491.23 (0.50–3.02)
-GTP 35 IU/L0.5250.75 (0.30–1.83)
TC 177 mg/dL0.0083.77 (1.41–10.05)0.01518.59 (1.78–193.65)
TG 88 mg/dL0.1012.60 (0.83–8.13)
LDL-C 98 mg/dL0.0284.91 (1.19–20.23)0.8001.25 (0.22–7.01)
StageF 3-40.4190.60 (0.17–2.07)
GradeA 2-30.8091.13 (0.41–3.18)
HCV RNA
<1000 KIU/mL0.3101.65 (0.63–4.31)

Relative risk (RR); 95% confidence interval (95% CI).